In order to improve therapeutic outcomes, precision exercise oncology must move toward personalized regimens that are tailored to individual characteristics, including tumor molecular markers (e.g., IDH mutation, MGMT methylation), functional capacity, treatment stage, and immune-metabolic profiles (443, 444). The gene discussed is IDH1; the disease is neoplasm.